Our research program is focused on antibodies for equine use. We believe that an antibody is useful to the immune system at any and all times. Vaccination programs are important and are your first line of defense . . . but even vaccinated animals become ill. Mg Biologics has been researching the benefit of plasma designed to support your horse during these highly stressful situations. Our theory is IV transfusion is beneficial and efficacious both after the exposure to a challenge and after the onset of symptoms. Antibodies, we believe, have the ability to reduce the duration of a disease, to reduce the severity of the disease or even to arrest the disease entirely.

Rhodococcus equi: We are currently hyper-immunizing research horses with three virulent R. equi strains. We finished an efficacy trial in 2004 and the data has recently been published. A PDF of the study, published in Veterinary Therapeutics can be viewed here.

Salmonella: We are working with a Salmonella Re mutant which is a Salmonella antibody as well as an anti-endotoxin. Initial research has shown benefits against gram negative organisms causing diarrhea and septicimia.

E. coli J-5: The E. coli strain we are studying is an anti-endotoxin. An efficacy trial has been set for January 2005 and will be to evaluate the effectiveness of anti-lipopolysaccharide hyper immune plasma as an aid in the control of Escherichia coli.

Clostridium perfringens A: We are researching the application of Clostridium perfringens A. Veterinarians have expressed a need for this specific antibody with antitoxins against Beta and enterotoxins, and as such, we hope to begin working with the USDA for efficacy testing.

Clostridium difficile: Our research is centered around a strain that has the A and B toxins. This
product will be researched in post-surgical care situations.

West Nile Virus: The NVSL in Ames have shown our research titers to be as high as 1:10,000. We hypothesize that early use of antibodies specific to WNV will reduce drug costs, reduce the duration of symptoms and reduce the severity of the disease. We have been collecting data from 2002 to present and plan to continue.

Streptococcus equi: We are currently working with USDA-CVB regarding conditional licensing on a Streptococcus Equi Antibody, Equine Origin. We have finished a trial evaluating the efficacy of plasma with S. equi antibodies when challenged with an S. equi organism.

Rotavirus: Our rotavirus titers have been tested at Purdue University and are as high as 1:16,000. A typical protective immune response is 1:64. Research will be focused on efficacy at low dosage levels.

Streptococcus zooepidemicus: Research is ongoing.

Clostridium botulinum B: Research is ongoing.